{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T16:40:03Z","timestamp":1786466403770,"version":"build-2736575974"},"reference-count":52,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,8,11]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Bispecific T-cell engagers (BiTEs) provide high rates of responses in patients with relapsed and refractory B-cell lymphomas and multiple myeloma otherwise resistant to other therapies, but the duration of response to these treatments is limited in time. Allogeneic stem cell transplantation is a potentially curative approach for those disorders, although its indication is limited to patients who achieve remission. With no established strategies to improve the \u201cgraft-versus-tumor effect\u201d available, relapses still account for most posttransplant failures. Here, we report, to our knowledge, the first case in literature of a successful treatment with glofitamab, a CD20X2\/CD3 BiTE, in a posttransplant relapse of mantle cell lymphoma with central nervous disease involvement. We propose the combination of BiTEs and allogeneic transplant as an integrated and sequential immunologic approach to be tested in clinical trials.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020530","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T20:55:50Z","timestamp":1779310550000},"page":"5227-5234","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":0,"title":["\u201cImmunologic dream team\u201d: BiTEs periallotransplant to redirect donor lymphocytes toward GVL"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3165-1899","authenticated-orcid":false,"given":"Lorenzo","family":"Iovino","sequence":"first","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3365-6562","authenticated-orcid":false,"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3573-2159","authenticated-orcid":false,"given":"Filippo","family":"Milano","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3023-6834","authenticated-orcid":false,"given":"Ajay K.","family":"Gopal","sequence":"additional","affiliation":[{"name":"1Fred Hutchinson Cancer Center, Seattle, WA"},{"name":"2Division of Hematology and Oncology, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,7,29]]},"reference":[{"issue":"1","key":"2026081110273744000_bib1","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1182\/hematology.2024000677","article-title":"Predicting bispecific antibody failure in diffuse large B-cell lymphoma","volume":"2024","author":"Barraclough","year":"2024","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"4","key":"2026081110273744000_bib2","doi-asserted-by":"crossref","DOI":"10.1016\/j.ccell.2023.02.008","article-title":"The pre-existing T cell landscape determines the response to bispecific T cell engagers in multiple myeloma patients","volume":"41","author":"Friedrich","year":"2023","journal-title":"Cancer Cell"},{"issue":"3","key":"2026081110273744000_bib3","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1182\/bloodadvances.2021005954","article-title":"Pharmacodynamics and molecular correlates of response to glofitamab in relapsed\/refractory non-Hodgkin lymphoma","volume":"6","author":"Br\u00f6ske","year":"2022","journal-title":"Blood Adv"},{"issue":"10","key":"2026081110273744000_bib4","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1182\/blood.2022015956","article-title":"T-cell exhaustion induced by continuous bispecific molecule exposure is ameliorated by treatment-free intervals","volume":"140","author":"Philipp","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026081110273744000_bib5","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1182\/blood.2023021672","article-title":"Sequential antigen loss and branching evolution in lymphoma after CD19- and CD20-targeted T-cell-redirecting therapy","volume":"143","author":"Duell","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026081110273744000_bib6","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1182\/blood-2023-184883","article-title":"Impact of prior bendamustine exposure on bispecific antibody treatment outcomes for patients with B-cell lymphoma","volume":"142","author":"Iacoboni","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026081110273744000_bib7","doi-asserted-by":"crossref","first-page":"380","DOI":"10.3324\/haematol.2018.200253","article-title":"Long-term follow up of tandem autologous-allogeneic hematopoietic cell transplantation for multiple myeloma","volume":"104","author":"Maffini","year":"2019","journal-title":"Haematologica"},{"issue":"1","key":"2026081110273744000_bib8","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1756-8722-6-2","article-title":"Comparative efficacy of tandem autologous versus autologous followed by allogeneic hematopoietic cell transplantation in patients with newly diagnosed multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"6","author":"Kharfan-Dabaja","year":"2013","journal-title":"J Hematol Oncol"},{"issue":"10","key":"2026081110273744000_bib9","first-page":"806.e1","article-title":"Long-term outcomes after allogeneic hematopoietic stem cell transplantation in relapsed\/refractory B-cell non-Hodgkin lymphoma: an Italian multicenter collaborative study","volume":"31","author":"Tarella","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"1","key":"2026081110273744000_bib10","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1038\/s41408-024-01085-9","article-title":"Hematopoietic stem cell transplantation for DLBCL: a report from the European Society for Blood and Marrow Transplantation on more than 40,000 patients over 32 years","volume":"14","author":"Berning","year":"2024","journal-title":"Blood Cancer J"},{"issue":"25","key":"2026081110273744000_bib11","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"2026081110273744000_bib12","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1016\/j.bbmt.2019.02.002","article-title":"Impact of donor type and melphalan dose on allogeneic transplantation outcomes for patients with lymphoma","volume":"25","author":"Saini","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"4","key":"2026081110273744000_bib13","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1200\/JCO.21.02293","article-title":"Randomized phase III BMT CTN trial of calcineurin inhibitor-free chronic graft-versus-host disease interventions in myeloablative hematopoietic cell transplantation for hematologic malignancies","volume":"40","author":"Luznik","year":"2022","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026081110273744000_bib14","doi-asserted-by":"crossref","first-page":"e409","DOI":"10.1016\/S2352-3026(19)30088-2","article-title":"Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial","volume":"6","author":"Sandmaier","year":"2019","journal-title":"Lancet Haematol"},{"issue":"5","key":"2026081110273744000_bib15","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1182\/blood.2021011994","article-title":"Bispecific antibodies for the treatment of B-cell lymphoma: promises, unknowns, and opportunities","volume":"141","author":"Falchi","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026081110273744000_bib16","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.trecan.2024.07.002","article-title":"Bispecific antibodies: advancing precision oncology","volume":"10","author":"Herrera","year":"2024","journal-title":"Trends Cancer"},{"issue":"4","key":"2026081110273744000_bib17","doi-asserted-by":"crossref","first-page":"332","DOI":"10.3960\/jslrt.24054","article-title":"Treatment with epcoritamab in 10 patients in real-world clinical practice","volume":"64","author":"Sekiguchi","year":"2024","journal-title":"J Clin Exp Hematop"},{"issue":"4","key":"2026081110273744000_bib18","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1182\/blood.2024024168","article-title":"Glofitamab stimulates immune cell infiltration of CNS tumors and induces clinical responses in secondary CNS lymphoma","volume":"144","author":"Godfrey","year":"2024","journal-title":"Blood"},{"issue":"12","key":"2026081110273744000_bib19","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1200\/JCO.22.01725","article-title":"Epcoritamab, a novel, subcutaneous CD3xCD20 bispecific T-cell-engaging antibody, in relapsed or refractory large B-cell lymphoma: dose expansion in a phase I\/II trial","volume":"41","author":"Thieblemont","year":"2023","journal-title":"J Clin Oncol"},{"issue":"8","key":"2026081110273744000_bib20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(22)00335-7","article-title":"Safety and efficacy of mosunetuzumab, a bispecific antibody, in patients with relapsed or refractory follicular lymphoma: a single-arm, multicentre, phase 2 study","volume":"23","author":"Budde","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"2026081110273744000_bib21","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1038\/s43018-025-00941-2","article-title":"Glofitamab in refractory or relapsed diffuse large B cell lymphoma after failing CAR-T cell therapy: a phase 2 LYSA study","volume":"6","author":"Cartron","year":"2025","journal-title":"Nat Cancer"},{"issue":"18","key":"2026081110273744000_bib22","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"2026081110273744000_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1056\/NEJMoa2203478","article-title":"Teclistamab in relapsed or refractory multiple myeloma","volume":"387","author":"Moreau","year":"2022","journal-title":"N Engl J Med"},{"issue":"9","key":"2026081110273744000_bib24","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1038\/s41591-023-02528-9","article-title":"Elranatamab in relapsed or refractory multiple myeloma: phase 2 MagnetisMM-3 trial results","volume":"29","author":"Lesokhin","year":"2023","journal-title":"Nat Med"},{"issue":"24","key":"2026081110273744000_bib25","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-cell\u2013redirecting GPRC5D bispecific antibody for multiple myeloma","volume":"387","author":"Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"2026081110273744000_bib26","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1038\/s41408-024-01139-y","article-title":"Bispecific antibodies in the treatment of multiple myeloma","volume":"14","author":"Devasia","year":"2024","journal-title":"Blood Cancer J"},{"issue":"1","key":"2026081110273744000_bib27","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41375-022-01739-2","article-title":"Outcomes of first therapy after CD19-CAR-T treatment failure in large B-cell lymphoma","volume":"37","author":"Alarcon Tomas","year":"2023","journal-title":"Leukemia"},{"issue":"24","key":"2026081110273744000_bib28","doi-asserted-by":"crossref","first-page":"2584","DOI":"10.1182\/blood.2022016945","article-title":"Outcomes of patients with aggressive B-cell lymphoma after failure of anti-CD19 CAR T-cell therapy: a DESCAR-T analysis","volume":"140","author":"Di Blasi","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026081110273744000_bib29","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1182\/bloodadvances.2024013640","article-title":"Impact of prior CAR T-cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas","volume":"9","author":"Chong","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026081110273744000_bib30","doi-asserted-by":"crossref","first-page":"e70079","DOI":"10.1002\/jha2.70079","article-title":"Early epcoritamab administration revives CAR-T cells in relapsed\/refractory B-cell lymphomas","volume":"6","author":"Yanashima","year":"2025","journal-title":"EJHaem"},{"issue":"12","key":"2026081110273744000_bib31","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"17","key":"2026081110273744000_bib32","doi-asserted-by":"crossref","first-page":"4926","DOI":"10.1182\/bloodadvances.2022009260","article-title":"Mosunetuzumab monotherapy is active and tolerable in patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"7","author":"Bartlett","year":"2023","journal-title":"Blood Adv"},{"key":"2026081110273744000_bib33","doi-asserted-by":"crossref","first-page":"1641769","DOI":"10.3389\/fonc.2025.1641769","article-title":"CD20xCD3 bispecific antibody achieved significant efficacy in patients with large B-cell lymphoma relapsing after or refractory to CAR-T therapy: a systematic review and meta-analysis","volume":"15","author":"Shen","year":"2025","journal-title":"Front Oncol"},{"issue":"5","key":"2026081110273744000_bib34","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2024.11.012","article-title":"Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives","volume":"25","author":"Waldschmidt","year":"2025","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"suppl 1","key":"2026081110273744000_bib35","article-title":"Mosunetuzumab monotherapy continues to demonstrate durable responses in patients with relapsed and\/or refractory follicular lymphoma after \u22652 prior therapies: 3-year follow-up from a pivotal phase II study","volume":"142","author":"Schuster","year":"2023","journal-title":"Blood"},{"issue":"11","key":"2026081110273744000_bib36","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/j.annonc.2024.08.2239","article-title":"Safety and efficacy of odronextamab in patients with relapsed or refractory follicular lymphoma","volume":"35","author":"Kim","year":"2024","journal-title":"Ann Oncol"},{"issue":"8","key":"2026081110273744000_bib37","doi-asserted-by":"crossref","first-page":"e593","DOI":"10.1016\/S2352-3026(24)00166-2","article-title":"Epcoritamab monotherapy in patients with relapsed or refractory follicular lymphoma (EPCORE NHL-1): a phase 2 cohort of a single-arm, multicentre study","volume":"11","author":"Linton","year":"2024","journal-title":"Lancet Haematol"},{"issue":"1","key":"2026081110273744000_bib38","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematol"},{"issue":"3","key":"2026081110273744000_bib39","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/bjh.70010","article-title":"Allogeneic transplantation after failure of chimeric antigen receptor-T cells and exposure to bispecific antibodies: Feasibility, safety and survival outcomes","volume":"207","author":"Barone","year":"2025","journal-title":"Br J Haematol"},{"issue":"8","key":"2026081110273744000_bib40","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/j.bbmt.2005.04.005","article-title":"Efficacy of reduced-intensity allogeneic stem cell transplantation in chemotherapy-refractory non-Hodgkin lymphoma","volume":"11","author":"Dean","year":"2005","journal-title":"Biol Blood Marrow Transpl"},{"issue":"9","key":"2026081110273744000_bib41","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"2026081110273744000_bib42","first-page":"520.e1","article-title":"Pretransplant blinatumomab improves outcomes in B cell acute lymphoblastic leukemia patients who undergo allogeneic hematopoietic cell transplantation","volume":"30","author":"Sayyed","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2026081110273744000_bib43","doi-asserted-by":"crossref","first-page":"107704","DOI":"10.1016\/j.leukres.2025.107704","article-title":"Pre-transplant blinatumomab and\/or inotuzumab ozogamicin therapy for relapsed\/refractory acute lymphoblastic and B\/myeloid mixed phenotype acute leukemia in adults","volume":"153","author":"Kondo","year":"2025","journal-title":"Leuk Res"},{"issue":"1","key":"2026081110273744000_bib44","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1182\/blood.2024024517","article-title":"How I treat postimmunotherapy relapsed B-ALL","volume":"145","author":"Lamble","year":"2025","journal-title":"Blood"},{"issue":"12","key":"2026081110273744000_bib45","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.1182\/blood.2021013290","article-title":"Blinatumomab maintenance after allogeneic hematopoietic cell transplantation for B-lineage acute lymphoblastic leukemia","volume":"139","author":"Gaballa","year":"2022","journal-title":"Blood"},{"issue":"4","key":"2026081110273744000_bib46","doi-asserted-by":"crossref","first-page":"e070051","DOI":"10.1136\/bmjopen-2022-070051","article-title":"Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed\/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21)","volume":"13","author":"Sakaguchi","year":"2023","journal-title":"BMJ Open"},{"key":"2026081110273744000_bib47","first-page":"329","article-title":"Post-transplant maintenance with blinatumomab for children, adolescents, and young adults with relapsed and refractory B-cell acute lymphoblastic leukemia: results of phase I in SCT-ALL-BLIN21","volume":"111","author":"Sakaguchi","year":"2026","journal-title":"Haematologica"},{"issue":"22","key":"2026081110273744000_bib48","doi-asserted-by":"crossref","first-page":"16105","DOI":"10.3390\/ijms242216105","article-title":"Blinatumomab redirects donor lymphocytes against CD19(+) acute lymphoblastic leukemia without relevant bystander alloreactivity after haploidentical hematopoietic stem cell transplantation","volume":"24","author":"Mancusi","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"2026081110273744000_bib49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1182\/blood-2024-208547","article-title":"Memory T-cell add back and prophylactic blinatumomab post Tcr\u03b1\u03b2 depleted haploidentical transplantation results in promising outcomes in pediatric patients with high-risk acute leukemia","volume":"144","author":"Naik","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026081110273744000_bib50","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1182\/bloodadvances.2025018152","article-title":"Allogeneic HCT as consolidation in B-cell lymphomas after exposure to bispecific antibodies: a GETH-TC study","volume":"10","author":"Pena","year":"2026","journal-title":"Blood Adv"},{"issue":"3","key":"2026081110273744000_bib51","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.3390\/ijms26031262","article-title":"Two are better than one: the bi-specific antibody mosunetuzumab reveals an improved immune response of V\u03b39V\u03b42 T cells targeting CD20 in malignant B cells in comparison to the mono-specific antibody obinutuzumab","volume":"26","author":"Marischen","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"suppl 1","key":"2026081110273744000_bib52","article-title":"V\u03b42 unconventional T cells in the donor graft are associated with improved overall survival after unrelated donor allo-HCT for AML and MDS: An analysis from the DKMS and NMDP graft composition study","volume":"146","author":"Markey","year":"2025","journal-title":"Blood"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5227\/2535573\/blooda_adv-2026-020530-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/15\/5227\/2535573\/blooda_adv-2026-020530-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T15:43:21Z","timestamp":1786463001000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/15\/5227\/568547\/Immunologic-dream-team-BiTEs-periallotransplant-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":52,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2026,8,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020530","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,8,11]]},"published":{"date-parts":[[2026,7,29]]}}}